EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study

Qinglong Li, Huagang Shi, Wei Hou, Tao Gu, Simao Song iD

Journal of Orthopaedic Surgery · 2026-05 · 34 (2)

DOI: 10.1177/10225536261470877 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Orthopaedic Surgery, online erschienen am 17.07.2026. Verfasst von Qinglong Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spinal Surgery and Neurosurgery, Sichuan Provincial Orthopedic Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Denosumab, Zoledronic Acid, Bone Density, Bone Density Conservation Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare the real-world effectiveness and safety of denosumab versus zoledronic acid in postmenopausal osteoporosis (PMO) and characterize baseline fracture risk profiles.

Methods

This retrospective cohort study included 250 PMO patients treated with denosumab (n = 148) or zoledronic acid (n = 102). Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates. The primary endpoint was 12-month change in lumbar spine bone mineral density (BMD). Fracture risk status was descriptively analyzed.

Results

The cohort was predominantly high-risk (98.4%). IPTW achieved adequate covariate balance. At 12 months, denosumab showed greater increases in lumbar spine BMD than zoledronic acid (6.09% vs. 4.82%; difference 1.27%, 95% CI: 0.474–2.067; P = 0.002), with consistent findings at the hip. Most adverse events were comparable between groups; however, acute phase reaction occurred significantly less frequently with denosumab, while no differences were observed in hypocalcemia or renal events.

Conclusion

Denosumab was associated with greater BMD gains than zoledronic acid over 12 months, with broadly comparable safety in a real-world PMO population. These findings are limited to short-term BMD outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabZoledronic AcidBone DensityBone Density Conservation AgentsOsteoporosis, PostmenopausalDiphosphonatesImidazolesHumansFemaleRetrospective StudiesAgedMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

adverse eventsbone mineral densitydenosumabhigh fracture riskpostmenopausal osteoporosisreal-world studyzoledronic acid

Substanzen

DenosumabZoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazoles

Autor:innen und Institutionen

  • Department of Spinal Surgery and Neurosurgery, Sichuan Provincial Orthopedic Hospital, Chengdu, China.

ORCID-Profile: Simao Song

Zitieren

APA

Li, Q., Shi, H., Hou, W., Gu, T., & Song, S. (2026). Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study. Journal of Orthopaedic Surgery, 34(2). https://doi.org/10.1177/10225536261470877

Vancouver

Li Q, Shi H, Hou W, Gu T, Song S. Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study. Journal of Orthopaedic Surgery. 2026;34(2). doi:10.1177/10225536261470877

BibTeX
@article{Li2026,
  author = {Li, Qinglong and Shi, Huagang and Hou, Wei and Gu, Tao and Song, Simao},
  title = {Real-world comparative effectiveness of denosumab versus zoledronic acid on bone mineral density changes in postmenopausal osteoporosis: An IPTW cohort study},
  journal = {Journal of Orthopaedic Surgery},
  year = {2026},
  volume = {34},
  number = {2},
  doi = {10.1177/10225536261470877}
}
Kostenlos starten →